XBI vs. GBPG.L

Last updated Jun 14, 2026

XBI (SPDR S&P Biotech ETF) and GBPG.L (Goldman Sachs Access UK Gilts 1-10 Years UCITS ETF Class GBP (Dist)) are both exchange-traded funds - XBI is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index, while GBPG.L is a European Government Bonds fund tracking the FTSE Act UK Cnvt Gilts All Stocks TR GBP. Both are passively managed. Over the past 3 years, XBI returned 14.23%/yr vs 6.35%/yr for GBPG.L. At a 0.28 correlation, their price movements are largely independent. XBI charges 0.35%/yr vs 0.07%/yr for GBPG.L.

Performance

XBI vs. GBPG.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in SPDR S&P Biotech ETF (XBI) and Goldman Sachs Access UK Gilts 1-10 Years UCITS ETF Class GBP (Dist) (GBPG.L). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

XBI is traded in USD, while GBPG.L is traded in GBP. To make them comparable, the GBPG.L values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, XBI achieves a 9.73% return, which is significantly higher than GBPG.L's 2.95% return.

XBI

• 1D: 0.79%
• 1M: -0.79%
• YTD: 9.73%
• 6M: 9.02%
• 1Y: 60.62%
• 3Y*: 14.23%
• 5Y*: -0.20%
• 10Y*: 9.55%

GBPG.L

• 1D: 0.12%
• 1M: 1.02%
• YTD: 2.95%
• 6M: 0.82%
• 1Y: 1.63%
• 3Y*: 6.35%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

XBI vs. GBPG.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
XBI SPDR S&P Biotech ETF	9.73%	35.89%	1.01%	7.60%	-25.87%	-16.57%
GBPG.L Goldman Sachs Access UK Gilts 1-10 Years UCITS ETF Class GBP (Dist)	2.95%	9.95%	-1.50%	9.78%	-18.86%	-2.95%

Correlation

The correlation between XBI and GBPG.L is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.35
Correlation (3Y) Calculated over the trailing 3-year period	0.27
Correlation (All Time) Calculated using the full available price history since Sep 7, 2021	0.28

Return for Risk

XBI vs. GBPG.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XBI

XBI Risk / Return Rank: 84
XBI Sharpe Ratio Rank: 82
XBI Sortino Ratio Rank: 81
XBI Omega Ratio Rank: 73
XBI Calmar Ratio Rank: 94
XBI Martin Ratio Rank: 90

GBPG.L

GBPG.L Risk / Return Rank: 18
GBPG.L Sharpe Ratio Rank: 17
GBPG.L Sortino Ratio Rank: 15
GBPG.L Omega Ratio Rank: 18
GBPG.L Calmar Ratio Rank: 20
GBPG.L Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XBI vs. GBPG.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and Goldman Sachs Access UK Gilts 1-10 Years UCITS ETF Class GBP (Dist) (GBPG.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	XBI	GBPG.L	Difference
Sharpe ratio: Return per unit of total volatility	2.28	0.09	+2.19
Sortino ratio: Return per unit of downside risk	3.11	0.20	+2.91
Omega ratio: Gain probability vs. loss probability	1.37	1.02	+0.34
Calmar ratio: Return relative to maximum drawdown	6.12	0.15	+5.97
Martin ratio: Return relative to average drawdown	18.07	0.34	+17.73

XBI vs. GBPG.L - Sharpe Ratio Comparison

The current XBI Sharpe Ratio is 2.28, which is higher than the GBPG.L Sharpe Ratio of 0.09. The chart below compares the historical Sharpe Ratios of XBI and GBPG.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

XBI vs. GBPG.L - Drawdown Comparison

The maximum XBI drawdown since its inception was -63.89%, which is greater than GBPG.L's maximum drawdown of -34.02%. Use the drawdown chart below to compare losses from any high point for XBI and GBPG.L.

Drawdown Indicators

	XBI	GBPG.L	Difference
Max Drawdown Largest peak-to-trough decline	-63.89%	-34.02%	-29.87%
Max Drawdown (1Y) Largest decline over 1 year	-9.72%	-5.89%	-3.83%
Max Drawdown (3Y) Largest decline over 3 years	-32.99%	-11.44%	-21.55%
Max Drawdown (5Y) Largest decline over 5 years	-54.71%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-63.89%	—	—
Current Drawdown Current decline from peak	-22.67%	-3.96%	-18.71%
Average Drawdown Average peak-to-trough decline	-20.93%	-12.52%	-8.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.30%	2.59%	+0.71%

Volatility

XBI vs. GBPG.L - Volatility Comparison

SPDR S&P Biotech ETF (XBI) has a higher volatility of 10.39% compared to Goldman Sachs Access UK Gilts 1-10 Years UCITS ETF Class GBP (Dist) (GBPG.L) at 2.47%. This indicates that XBI's price experiences larger fluctuations and is considered to be riskier than GBPG.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XBI	GBPG.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.39%	2.47%	+7.92%
Volatility (6M) Calculated over the trailing 6-month period	20.76%	7.65%	+13.11%
Volatility (1Y) Calculated over the trailing 1-year period	26.09%	9.53%	+16.56%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.21%	10.74%	+21.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.01%	10.74%	+21.27%

XBI vs. GBPG.L - Expense Ratio Comparison

XBI has a 0.35% expense ratio, which is higher than GBPG.L's 0.07% expense ratio.

Dividends

XBI vs. GBPG.L - Dividend Comparison

XBI's dividend yield for the trailing twelve months is around 0.33%, less than GBPG.L's 4.08% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GBPG.L Goldman Sachs Access UK Gilts 1-10 Years UCITS ETF Class GBP (Dist)	4.08%	4.13%	4.10%	3.35%	0.63%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XBI SPDR S&P Biotech ETF	0.33%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Frequently Asked Questions

Can I hold both XBI and GBPG.L in my portfolio?

XBI and GBPG.L have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, XBI or GBPG.L?

On fees, GBPG.L is cheaper at 0.07% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, XBI or GBPG.L?

GBPG.L is cheaper with a 0.07% expense ratio, compared with 0.35% for XBI.

What is the main difference between XBI and GBPG.L?

XBI is categorized as Health & Biotech Equities, while GBPG.L is European Government Bonds. XBI tracks S&P Biotechnology Select Industry Index, while GBPG.L tracks FTSE Act UK Cnvt Gilts All Stocks TR GBP. They also come from different issuers: State Street and Goldman Sachs. Their fees differ too: 0.35% for XBI and 0.07% for GBPG.L.